Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico — Oct 15th, 2024

Knight Therapeutics MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory appro...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico — Oct 15th, 2024

Knight Therapeutics MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory appro...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico — Oct 15th, 2024

Knight Therapeutics MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory appro...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico — Oct 15th, 2024

Knight Therapeutics MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory appro...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico — Oct 15th, 2024

Knight Therapeutics MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory appro...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico — Oct 15th, 2024

Knight Therapeutics MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory appro...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico — Oct 15th, 2024

Knight Therapeutics MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory appro...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico — Oct 15th, 2024

Knight Therapeutics MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory appro...

Knight Therapeutics Announces Launch of Minjuvi® in Brazil — Feb 29th, 2024

Knight Therapeutics MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi® is in...